Trial · NCT06398444
A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
NCT06398444, Phase 2, Phase 3, Recruiting, Sinotau Pharmaceutical Group
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms. Trials, record NCT06398444. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06398444
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
- NCT number
- NCT06398444
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 85 participants, estimated
- Lead sponsor
- Sinotau Pharmaceutical Group
- Conditions
- Advanced Neuroendocrine Neoplasm
- Interventions
- Lutetium[177Lu] Oxodotreotide Injection
- First posted
- 2024-05-03
- Last updated
- 2026-07-17
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and severity of adverse events (AE) (Part1) | Until 6 months after the last dose | |
| Primary | Overall Response Rate (ORR) assessed by Independent Review Committee (IRC) (Part 2) | Until disease progression or death, up to 5 years | |
| Secondary | Overall Response Rate (ORR) (Part 1) | Until disease progression or death, up to 5 years | |
| Secondary | Progression-free survival (PFS) (Part 1) | Until disease progression or death, up to 5 years | |
| Secondary | Disease Control Rate (DCR) (Part 1) | Until disease progression or death, up to 5 years | |
| Secondary | Duration of Overall Response (DoR) (Part 1) | Until disease progression or death, up to 5 years | |
| Secondary | Time to Progression (TTP) (Part 1) | Until disease progression or death, up to 5 years | |
| Secondary | PFS rate at 12 months (Part 1) | At 12 months after the first dose | |
| Secondary | Overall Survival (OS) (Part 1) | Until death of any cause, up to 5 years | |
| Secondary | Change From Baseline in the EORTC QLQ-C30 Questionnaire (Part 1) | Until disease progression or death, up to 5 years |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06398444
GET https://conductscience.org/api/trials/v1/NCT06398444/registered